688553 汇宇制药
已收盘 04-17 15:00:01
资讯
新帖
简况
每周股票复盘:汇宇制药(688553)股东黄干益股份被司法强制执行
证券之星 · 54分钟前
每周股票复盘:汇宇制药(688553)股东黄干益股份被司法强制执行
汇宇制药(688553)披露持股5%以上股东股份被司法强制执行的提示性公告,4月17日股价上涨0.05%
证券之星 · 04-17 17:33
汇宇制药(688553)披露持股5%以上股东股份被司法强制执行的提示性公告,4月17日股价上涨0.05%
汇宇制药跌5.43% 上市即巅峰募24.7亿中信建投保荐
中金财经 · 04-10
汇宇制药跌5.43% 上市即巅峰募24.7亿中信建投保荐
4月9日汇宇制药跌12.24%,大摩健康产业混合A基金重仓该股
证券之星 · 04-09
4月9日汇宇制药跌12.24%,大摩健康产业混合A基金重仓该股
汇宇制药(688553.SH)产品获得境外上市许可
智通财经 · 04-09
汇宇制药(688553.SH)产品获得境外上市许可
4月7日汇宇制药涨7.48%,大摩健康产业混合A基金重仓该股
证券之星 · 04-07
4月7日汇宇制药涨7.48%,大摩健康产业混合A基金重仓该股
每周股票复盘:汇宇制药(688553)股价连续两日大幅上涨
证券之星 · 04-05
每周股票复盘:汇宇制药(688553)股价连续两日大幅上涨
汇宇制药(688553)披露股票交易异常波动公告,4月3日股价上涨4.77%
证券之星 · 04-03
汇宇制药(688553)披露股票交易异常波动公告,4月3日股价上涨4.77%
汇宇制药:主要创新药研发管线尚处于临床研究阶段具有较大不确定性
证券之星 · 04-02
汇宇制药:主要创新药研发管线尚处于临床研究阶段具有较大不确定性
4月1日汇宇制药(688553)龙虎榜数据:机构净卖出944.35万元
证券之星 · 04-01
4月1日汇宇制药(688553)龙虎榜数据:机构净卖出944.35万元
3月27日汇宇制药涨6.98%,大摩健康产业混合A基金重仓该股
证券之星 · 03-27
3月27日汇宇制药涨6.98%,大摩健康产业混合A基金重仓该股
3月23日汇宇制药跌5.94%,大摩健康产业混合A基金重仓该股
证券之星 · 03-23
3月23日汇宇制药跌5.94%,大摩健康产业混合A基金重仓该股
每周股票复盘:汇宇制药(688553)股东拟减持不超3%股份
证券之星 · 03-22
每周股票复盘:汇宇制药(688553)股东拟减持不超3%股份
3月20日汇宇制药创60日新低,大摩健康产业混合A基金重仓该股
证券之星 · 03-20
3月20日汇宇制药创60日新低,大摩健康产业混合A基金重仓该股
汇宇制药(688553.SH)股东王晓鹏拟减持不超3%股份
智通财经 · 03-16
汇宇制药(688553.SH)股东王晓鹏拟减持不超3%股份
汇宇制药:注射用卡非佐米获得药品注册证书
证券之星 · 03-13
汇宇制药:注射用卡非佐米获得药品注册证书
每周股票复盘:汇宇制药(688553)业绩快报更正致公允价值变动收益调减1.73亿
证券之星 · 03-08
每周股票复盘:汇宇制药(688553)业绩快报更正致公允价值变动收益调减1.73亿
汇宇制药(688553)披露2025年度业绩快报更正公告,3月2日股价下跌2.57%
证券之星 · 03-02
汇宇制药(688553)披露2025年度业绩快报更正公告,3月2日股价下跌2.57%
汇宇制药:修正2025年度业绩快报确认公允价值变动收益为-1.73亿元
证券之星 · 03-01
汇宇制药:修正2025年度业绩快报确认公允价值变动收益为-1.73亿元
汇宇制药发布2025年度业绩快报,亏损0.242亿元
证券之星 · 02-27
汇宇制药发布2025年度业绩快报,亏损0.242亿元
公司概况
公司名称:
四川汇宇制药股份有限公司
所属行业:
医药制造业
上市日期:
2021-10-26
主营业务:
四川汇宇制药股份有限公司的主营业务是肿瘤治疗领域创新药和优质仿制药的研发、生产和国内外销售。公司的主要产品是原料药、抗肿瘤注射剂、肿瘤辅助用药等。公司荣登“2022年四川省新经济100强企业榜单”;荣获“四川省2022年度科技创新引才引智先进基地”;荣获“2023年中国医药新锐创新力量”;荣获“四川企业技术创新发展能力100强”且名次跃升至第6位;再次斩获“四川企业技术创新发展最具潜力20强企业”;荣获“2023年度科技人才工作先进单位”表彰授牌。
发行价格:
38.87
{"stockData":{"symbol":"688553","market":"SH","secType":"STK","nameCN":"汇宇制药","latestPrice":19.94,"timestamp":1776409201000,"preClose":19.93,"halted":0,"volume":9788571,"delay":0,"changeRate":0.0005,"floatShares":344000000,"shares":424000000,"eps":0.1116,"marketStatus":"已收盘","change":0.01,"latestTime":"04-17 15:00:01","open":19.82,"high":20.55,"low":19.65,"amount":196000000,"amplitude":0.0452,"askPrice":19.94,"askSize":190,"bidPrice":19.93,"bidSize":54,"shortable":0,"etf":0,"ttmEps":0.1116,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":5,"adr":0,"adjPreClose":19.93,"symbolType":"stock_kcb","openAndCloseTimeList":[[1776389400000,1776396600000],[1776402000000,1776409200000]],"highLimit":21.92,"lowLimit":17.94,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":423600000,"isCdr":false,"pbRate":2.26,"roa":"--","peRate":178.673835,"roe":"--","epsLYR":0.77,"committee":0.150877,"marketValue":8447000000,"turnoverRate":0.0285,"status":0,"afterMarket":{"amount":0,"volume":0,"close":19.94,"buyVolume":200,"sellVolume":0,"time":1776411237558,"indexStatus":"已收盘 04-17 15:30:00","preClose":19.93},"floatMarketCap":6850000000},"requestUrl":"/m/hq/s/688553/wiki","defaultTab":"wiki","newsList":[{"id":"2628775920","title":"每周股票复盘:汇宇制药(688553)股东黄干益股份被司法强制执行","url":"https://stock-news.laohu8.com/highlight/detail?id=2628775920","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628775920?lang=zh_cn&edition=full","pubTime":"2026-04-19 03:05","pubTimestamp":1776539110,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘,汇宇制药报收于19.94元,较上周的20.01元下跌0.35%。本周,汇宇制药4月16日盘中最高价报20.58元。本周关注点来自公司公告汇总:持股5%以上股东黄干益所持19,628,307股将被司法强制变现。来自公司公告汇总:独立董事梁昕昕、龙永强任期届满将离任,董事会换届延期。公司公告汇总持股5%以上股东黄干益持有公司股份25,919,439股,占总股本的6.119%,股份状态为全部冻结。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628272362","title":"汇宇制药(688553)披露持股5%以上股东股份被司法强制执行的提示性公告,4月17日股价上涨0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628272362","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628272362?lang=zh_cn&edition=full","pubTime":"2026-04-17 17:33","pubTimestamp":1776418414,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘,汇宇制药报收于19.94元,较前一交易日上涨0.05%,最新总市值为84.47亿元。近日,四川汇宇制药股份有限公司发布《持股5%以上股东所持股份被司法强制执行的提示性公告》。公告显示,截至2026年4月17日,公司持股5%以上股东黄干益持有公司股份25,919,439股,占总股本的6.119%,股份状态为全部冻结。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700033461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626719323","title":"汇宇制药跌5.43% 上市即巅峰募24.7亿中信建投保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2626719323","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626719323?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:09","pubTimestamp":1775812165,"startTime":"0","endTime":"0","summary":"中国经济网北京4月10日讯 汇宇制药 今日收报20.01元,跌幅5.43%。 2021年10月26日,汇宇制药在上交所科创板上市,公开发行股票6360.00万股,发行价格为38.87元/股,保荐机构、主承销商为中信建投证券,保荐代表人为杨泉、田斌,联席主承销商为国都证券。 上市当日,汇宇制药盘中最高报42.59元,创上市以来股价最高点。 汇宇制药发行费用合计1.11亿元,其中中信建投证券、国都证券获得承销费9887.48万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260410/32136691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["601066","688553","BK0276","BK0239","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902984","title":"4月9日汇宇制药跌12.24%,大摩健康产业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902984","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626902984?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:21","pubTimestamp":1775722882,"startTime":"0","endTime":"0","summary":"证券之星消息,4月9日汇宇制药跌12.24%创60日新高,收盘报21.16元,换手率11.65%,成交量40.02万手,成交额9.21亿元。4月9日的资金流向数据方面,主力资金净流出1.58亿元,占总成交额17.11%,游资资金净流入2245.49万元,占总成交额2.44%,散户资金净流入1.35亿元,占总成交额14.67%。重仓汇宇制药的公募基金请见下表:根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为摩根士丹利基金的大摩健康产业混合A。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900025344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626904856","title":"汇宇制药(688553.SH)产品获得境外上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2626904856","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626904856?lang=zh_cn&edition=full","pubTime":"2026-04-09 15:47","pubTimestamp":1775720876,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药 发布公告,公司子公司Seacross Pharma Ltd.和 Seacross Pharmaceuticals Ltd.于近期分别收到德国联邦药品和医疗器械管理局、西班牙药品和医疗器械管理局、比利时联邦药品和保健品管理局、巴基斯坦药品监管局和卫生部核准签发的公司产品注射用替考拉宁、注射用紫杉醇、醋酸奥曲肽注射液的上市许可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426487.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","IPOS","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625993320","title":"4月7日汇宇制药涨7.48%,大摩健康产业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625993320","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625993320?lang=zh_cn&edition=full","pubTime":"2026-04-07 16:20","pubTimestamp":1775550031,"startTime":"0","endTime":"0","summary":"证券之星消息,4月7日汇宇制药涨7.48%创60日新高,收盘报24.56元,换手率12.15%,成交量41.74万手,成交额10.13亿元。重仓汇宇制药的公募基金请见下表:根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为摩根士丹利基金的大摩健康产业混合A。该公募基金现任基金经理为王大鹏。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700021910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625616407","title":"每周股票复盘:汇宇制药(688553)股价连续两日大幅上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2625616407","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625616407?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:20","pubTimestamp":1775326823,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,汇宇制药报收于22.85元,较上周的17.31元上涨32.0%。本周,汇宇制药4月3日盘中最高价报23.0元。沪深交易所2026年4月1日公布的交易公开信息显示,汇宇制药因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。公司公告汇总股票交易异常波动公告四川汇宇制药股份有限公司股票于2026年4月1日和4月2日连续两个交易日内收盘价格涨幅偏离值累计达到30%,构成股票交易异常波动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624663886","title":"汇宇制药(688553)披露股票交易异常波动公告,4月3日股价上涨4.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624663886","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624663886?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:17","pubTimestamp":1775225836,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,汇宇制药报收于22.85元,较前一交易日上涨4.77%,最新总市值为96.79亿元。公司于2026年4月3日发布《股票交易异常波动公告》。公告显示,汇宇制药股票于2026年4月1日和4月2日连续两个交易日内收盘价格涨幅偏离值累计达到30%,构成股票交易异常波动。公司经自查并问询控股股东、实际控制人,确认截至目前不存在应披露而未披露的重大事项。股票异常波动期间,公司董事、高管、控股股东等不存在买卖公司股票的行为。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624245574","title":"汇宇制药:主要创新药研发管线尚处于临床研究阶段具有较大不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2624245574","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624245574?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:01","pubTimestamp":1775120488,"startTime":"0","endTime":"0","summary":"汇宇制药(688553.SH)发布股票交易异常波动公告称,经自查,公司主要创新药研发管线尚处于临床研究阶段,未来还需经历临床研究、新药上市申请等研发阶段,具有较大不确定性;不排除创新药研发过程中还可能会面临研发失败、研发进度不及预期、行业环境变化、市场竞争加剧等诸多潜在风险。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200028237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553","159992","06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624994175","title":"4月1日汇宇制药(688553)龙虎榜数据:机构净卖出944.35万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624994175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624994175?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:21","pubTimestamp":1775035274,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年4月1日公布的交易公开信息显示,汇宇制药因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月1日收盘,汇宇制药报收于19.69元,上涨17.9%,换手率6.59%,成交量22.64万手,成交额4.32亿元。从龙虎榜公布的当日买卖数据来看,机构合计净卖出944.35万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100031666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622849806","title":"3月27日汇宇制药涨6.98%,大摩健康产业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622849806","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622849806?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:14","pubTimestamp":1774599249,"startTime":"0","endTime":"0","summary":"证券之星消息,3月27日汇宇制药涨6.98%,收盘报17.31元,换手率1.84%,成交量6.31万手,成交额1.08亿元。重仓汇宇制药的公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为摩根士丹利基金的大摩健康产业混合A。该公募基金现任基金经理为王大鹏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621776500","title":"3月23日汇宇制药跌5.94%,大摩健康产业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621776500","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621776500?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:41","pubTimestamp":1774255295,"startTime":"0","endTime":"0","summary":"证券之星消息,3月23日汇宇制药跌5.94%创60日新低,收盘报15.2元,换手率1.65%,成交量5.68万手,成交额8890.43万元。重仓汇宇制药的公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为摩根士丹利基金的大摩健康产业混合A。该公募基金现任基金经理为王大鹏。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621379603","title":"每周股票复盘:汇宇制药(688553)股东拟减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2621379603","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621379603?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:25","pubTimestamp":1774117514,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘,汇宇制药报收于16.16元,较上周的17.77元下跌9.06%。本周,汇宇制药3月16日盘中最高价报18.17元。本周关注点公司公告汇总:股东王晓鹏拟减持不超过公司总股本的3%公司公告汇总股东王晓鹏女士持有公司股份16,698,125股,占公司总股本的3.942%,股份来源于首次公开发行前取得,已解除限售。因自身资金需求,拟通过集中竞价和大宗交易方式减持不超过12,708,000股,减持比例不超过公司总股本的3%,减持期间为2026年4月8日至2026年7月6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620786633","title":"3月20日汇宇制药创60日新低,大摩健康产业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620786633","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620786633?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:18","pubTimestamp":1773994733,"startTime":"0","endTime":"0","summary":"证券之星消息,3月20日汇宇制药跌5.28%创60日新低,收盘报16.16元,换手率1.62%,成交量5.57万手,成交额9259.38万元。重仓汇宇制药的公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为摩根士丹利基金的大摩健康产业混合A。该公募基金现任基金经理为王大鹏。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000027599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619507024","title":"汇宇制药(688553.SH)股东王晓鹏拟减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2619507024","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619507024?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:20","pubTimestamp":1773663600,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药(688553.SH)发布公告,因自身资金需求,股东王晓鹏女士拟通过集中竞价和大宗交易的方式合计减持公司股份不超过1270.8万股,合计减持比例不超过公司股份总数的3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619195100","title":"汇宇制药:注射用卡非佐米获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619195100","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619195100?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:20","pubTimestamp":1773397202,"startTime":"0","endTime":"0","summary":"汇宇制药(688553.SH)公告称,公司近日收到国家药品监督管理局核准签发的公司产品注射用卡非佐米的《药品注册证书》。注射用卡非佐米主要适应症为多发性骨髓瘤,公司研发的注射用卡非佐米通过仿制药一致性评价,提升了自身的竞争能力,对公司的发展起到积极作用。但产品注册批件的取得在短期内对公司经营业绩不构成重大影响。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300032889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617566813","title":"每周股票复盘:汇宇制药(688553)业绩快报更正致公允价值变动收益调减1.73亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2617566813","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617566813?lang=zh_cn&edition=full","pubTime":"2026-03-08 01:50","pubTimestamp":1772905817,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘,汇宇制药报收于18.32元,较上周的19.1元下跌4.08%。本周,汇宇制药3月2日盘中最高价报19.0元。本周关注点公司公告汇总:2025年度业绩快报更正,公允价值变动收益由1.73亿元更正为-1.73亿元公司公告汇总四川汇宇制药股份有限公司对2025年度业绩快报进行更正,主要涉及被投资企业浙江同源康医药股份有限公司在香港交易所上市后,公司确认的公允价值变动收益由1.73亿元更正为-1.73亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616551380","title":"汇宇制药(688553)披露2025年度业绩快报更正公告,3月2日股价下跌2.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616551380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616551380?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:40","pubTimestamp":1772444454,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘,汇宇制药报收于18.61元,较前一交易日下跌2.57%,最新总市值为78.83亿元。该股当日开盘18.82元,最高19.0元,最低18.18元,成交额达1.21亿元,换手率为1.9%。公司于近日披露《2025年度业绩快报更正公告》。公告显示,因被投资企业浙江同源康医药股份有限公司在香港交易所上市后,公司确认的公允价值变动收益由1.73亿元更正为-1.73亿元,公司对2025年度业绩快报相关内容进行更正。本次更正不影响其他财务数据,最终数据以年度报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200026369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616826764","title":"汇宇制药:修正2025年度业绩快报确认公允价值变动收益为-1.73亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616826764","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616826764?lang=zh_cn&edition=full","pubTime":"2026-03-01 16:49","pubTimestamp":1772354972,"startTime":"0","endTime":"0","summary":"汇宇制药(688553.SH)发布2025年度业绩快报更正公告,报告期内,公司被投资企业浙江同源康医药股份有限公司在香港交易所上市,公司直接持有的其股权在报告期内确认公允价值变动收益为-1.73亿元。除上述更正内容外,原公告其他内容不变,由此给投资者带来的不便,公司深表歉意,敬请广大投资者谅解。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100005506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614083835","title":"汇宇制药发布2025年度业绩快报,亏损0.242亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614083835","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614083835?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:24","pubTimestamp":1772184275,"startTime":"0","endTime":"0","summary":"证券之星消息,汇宇制药近日即将发布2025年年报,根据2月27日发布的业绩快报,归属净利润亏损0.242亿元,同比减少107.44%。影响报告期业绩的主要因素:报告期内,集采政策持续深化,公司对国家集中带量采购政策积极贯彻执行,相关产品价格、利润下降,对公司业绩产生影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700029054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776542321428,"stockEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.133},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0473},{"period":"1year","weight":0.3432},{"period":"ytd","weight":0.1209}],"compareEarnings":[{"period":"1week","weight":0.0164},{"period":"1month","weight":-0.0028},{"period":"3month","weight":-0.0123},{"period":"6month","weight":0.0551},{"period":"1year","weight":0.2351},{"period":"ytd","weight":0.0208}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川汇宇制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13908人(较上一季度减少14.45%)","perCapita":"24700股","listingDate":"2021-10-26","address":"四川省内江市市中区汉阳路333号3幢","registeredCapital":"42360万元","survey":" 四川汇宇制药股份有限公司的主营业务是肿瘤治疗领域创新药和优质仿制药的研发、生产和国内外销售。公司的主要产品是原料药、抗肿瘤注射剂、肿瘤辅助用药等。公司荣登“2022年四川省新经济100强企业榜单”;荣获“四川省2022年度科技创新引才引智先进基地”;荣获“2023年中国医药新锐创新力量”;荣获“四川企业技术创新发展能力100强”且名次跃升至第6位;再次斩获“四川企业技术创新发展最具潜力20强企业”;荣获“2023年度科技人才工作先进单位”表彰授牌。","listedPrice":38.87},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汇宇制药(688553)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汇宇制药,688553,汇宇制药股票,汇宇制药股票老虎,汇宇制药股票老虎国际,汇宇制药行情,汇宇制药股票行情,汇宇制药股价,汇宇制药股市,汇宇制药股票价格,汇宇制药股票交易,汇宇制药股票购买,汇宇制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汇宇制药(688553)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}